The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of BLX-3030, a potent and selective inhibitor of CDK9 for the treatment of NMYC-driven NEPCS.
 
Kyle Medley
Employment - Biolexis Therapeutics
Leadership - Biolexis Therapeutics
Stock and Other Ownership Interests - Biolexis Therapeutics
 
Zhaoliang Li
Employment - Biolexis Therapeutics
 
Chenyu Lin
Employment - Biolexis Therapeutics
 
David J Bearss
Employment - Biolexis Therapeutics; Halia Therapeutics
Leadership - Biolexis Therapeutics; Halia Therapeutics
Stock and Other Ownership Interests - Biolexis Therapeutics; Halia Therapeutics
 
Hariprasad Vankayalapati
Employment - Biolexis Therapeutics
Leadership - Arrien Pharmaceuticals; Biolexis Therapeutics
Stock and Other Ownership Interests - Arrien Pharmaceuticals; Biolexis Therapeutics